JP2022087255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022087255A5 JP2022087255A5 JP2022066452A JP2022066452A JP2022087255A5 JP 2022087255 A5 JP2022087255 A5 JP 2022087255A5 JP 2022066452 A JP2022066452 A JP 2022066452A JP 2022066452 A JP2022066452 A JP 2022066452A JP 2022087255 A5 JP2022087255 A5 JP 2022087255A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- nanoparticles
- nanoparticle
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 31
- 239000002105 nanoparticle Substances 0.000 claims 21
- 108010088751 Albumins Proteins 0.000 claims 5
- 102000009027 Albumins Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140647A JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206772P | 2015-08-18 | 2015-08-18 | |
| US201562206771P | 2015-08-18 | 2015-08-18 | |
| US201562206770P | 2015-08-18 | 2015-08-18 | |
| US62/206,771 | 2015-08-18 | ||
| US62/206,770 | 2015-08-18 | ||
| US62/206,772 | 2015-08-18 | ||
| PCT/US2015/054295 WO2016057554A1 (en) | 2014-10-06 | 2015-10-06 | Carrier-antibody compositions and methods of making and using the same |
| USPCT/US2015/054295 | 2015-10-06 | ||
| USPCT/US2016/026270 | 2016-04-06 | ||
| PCT/US2016/026270 WO2017176265A1 (en) | 2016-04-06 | 2016-04-06 | Carrier-binding agent compositions and methods of making and using the same |
| JP2021025180A JP7133050B2 (ja) | 2015-08-18 | 2021-02-19 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021025180A Division JP7133050B2 (ja) | 2015-08-18 | 2021-02-19 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140647A Division JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022087255A JP2022087255A (ja) | 2022-06-09 |
| JP2022087255A5 true JP2022087255A5 (https=) | 2022-09-15 |
Family
ID=58051595
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506415A Active JP6921802B2 (ja) | 2015-08-18 | 2016-08-18 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2021025180A Active JP7133050B2 (ja) | 2015-08-18 | 2021-02-19 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2022066452A Withdrawn JP2022087255A (ja) | 2015-08-18 | 2022-04-13 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2022140647A Withdrawn JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506415A Active JP6921802B2 (ja) | 2015-08-18 | 2016-08-18 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2021025180A Active JP7133050B2 (ja) | 2015-08-18 | 2021-02-19 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140647A Withdrawn JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250170067A1 (https=) |
| EP (1) | EP3337823A4 (https=) |
| JP (4) | JP6921802B2 (https=) |
| CN (2) | CN108290944B (https=) |
| AU (1) | AU2016308337B2 (https=) |
| CA (1) | CA2995384A1 (https=) |
| IL (1) | IL256621A (https=) |
| WO (1) | WO2017031368A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| EP3834889A1 (en) | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| JP6921802B2 (ja) * | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | キャリア結合剤組成物およびそれを作製および使用する方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| AU2021236234A1 (en) * | 2020-03-11 | 2022-10-06 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| EP4208204A1 (en) | 2020-09-02 | 2023-07-12 | Mayo Foundation for Medical Education and Research | Antibody-nanoparticle complexes and methods for making and using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146833A (ja) * | 1984-01-10 | 1985-08-02 | Green Cross Corp:The | モノクロ−ナル抗体製剤 |
| JPS6178731A (ja) * | 1985-05-20 | 1986-04-22 | Green Cross Corp:The | 加熱処理免疫グロブリン製剤 |
| EP0465513A1 (en) * | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008109163A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CA2721093A1 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| US10413606B2 (en) * | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| EP2953622B1 (en) * | 2013-02-11 | 2021-03-24 | Abraxis BioScience, LLC | Methods of treating melanoma |
| DK3204413T3 (da) * | 2014-10-06 | 2019-12-09 | Mayo Found Medical Education & Res | Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
| JP6921802B2 (ja) | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | キャリア結合剤組成物およびそれを作製および使用する方法 |
-
2016
- 2016-08-18 JP JP2018506415A patent/JP6921802B2/ja active Active
- 2016-08-18 CN CN201680047942.2A patent/CN108290944B/zh active Active
- 2016-08-18 CN CN202210483706.2A patent/CN114796130B/zh active Active
- 2016-08-18 CA CA2995384A patent/CA2995384A1/en active Pending
- 2016-08-18 WO PCT/US2016/047641 patent/WO2017031368A1/en not_active Ceased
- 2016-08-18 AU AU2016308337A patent/AU2016308337B2/en not_active Ceased
- 2016-08-18 EP EP16837869.3A patent/EP3337823A4/en active Pending
-
2017
- 2017-12-27 IL IL256621A patent/IL256621A/en unknown
-
2021
- 2021-02-19 JP JP2021025180A patent/JP7133050B2/ja active Active
-
2022
- 2022-04-13 JP JP2022066452A patent/JP2022087255A/ja not_active Withdrawn
- 2022-09-05 JP JP2022140647A patent/JP2022164916A/ja not_active Withdrawn
-
2024
- 2024-07-26 US US18/785,952 patent/US20250170067A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022087255A5 (https=) | ||
| JP2021075579A5 (https=) | ||
| Kumari et al. | Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics | |
| Batool et al. | A detailed insight of the tumor targeting using nanocarrier drug delivery system | |
| Emami et al. | Doxorubicin and anti-PD-L1 antibody conjugated gold nanoparticles for colorectal cancer photochemotherapy | |
| Li et al. | Be active or not: the relative contribution of active and passive tumor targeting of nanomaterials | |
| US20200246482A1 (en) | Anticancer drug-containing plant virus particles | |
| Taheri et al. | Trastuzumab decorated methotrexate–human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells | |
| Shukla et al. | Affinity of plant viral nanoparticle potato virus X (PVX) towards malignant B cells enables cancer drug delivery | |
| CN105288639A (zh) | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 | |
| Safdari et al. | Use of single-chain antibody derivatives for targeted drug delivery | |
| Wu et al. | Peptide-functionalized nanoinhibitor restrains brain tumor growth by abrogating mesenchymal-epithelial transition factor (MET) signaling | |
| JP2020506924A5 (https=) | ||
| KR20210125603A (ko) | 골수종의 치료 | |
| Sao et al. | Multifunctional drug delivery systems using inorganic nanomaterials: a review | |
| CN103599068A (zh) | 纳米载药胶束和抗癌药物及其制备方法 | |
| WO2021104414A1 (zh) | 一种细胞表面偶联抗体的方法及其应用 | |
| CN104491868B (zh) | 新型基于抗体偶联化疗药物纳米adc及制备方法和应用 | |
| JPWO2022020105A5 (https=) | ||
| WO2021245539A1 (ko) | 약물 전달과 내재화 효율이 강화된 약물복합체 | |
| Barkovich et al. | iRGD‐Targeted Physalis Mottle Virus Like Nanoparticles for Targeted Cancer Delivery | |
| CN104758946A (zh) | 一种抗体偶联药物及其制备方法和应用 | |
| Hirata et al. | A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes | |
| Wu et al. | Inflammation-targeted drug delivery strategies via albumin-based systems | |
| ES2505890T3 (es) | Conjugados que comprenden nanopartículas recubiertas con compuestos que contienen platino |